Skip to main content
Pharmaids Pharmaceuticals Ltd. logo

Pharmaids Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · 524572 ISIN · INE117D01018 LEI · 64881R93DKT67Q1W7C21 BSE.NS Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-31 Earnings Release
Country IN India
Listing BSE.NS 524572

About Pharmaids Pharmaceuticals Ltd.

https://www.pharmaids.com

Pharmaids Pharmaceuticals Ltd. specializes in the formulation, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its core portfolio encompasses various delivery systems, including solid orals like tablets and capsules, as well as liquid preparations, topical ointments, and injectables. The company addresses diverse therapeutic categories such as anti-infectives, analgesics, gastrointestinal health, and nutritional support. Committed to stringent quality assurance and research-led development, the organization focuses on delivering standardized medicinal solutions. Its operational framework prioritizes regulatory compliance and the optimization of manufacturing processes to support healthcare delivery across multiple clinical segments.

Recent filings

Filing Released Lang Actions
Newspaper publication of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026
Earnings Release Classification · 78% confidence The document is composed of multiple newspaper advertisements and regulatory exchange notices disclosing the audited financial results for the quarter and full year ended March 31, 2026. It provides summarized revenue and profit figures, refers to the Independent Auditors’ Report, and was published pursuant to SEBI listing regulations. This is not a full annual 10-K nor a proxy or governance statement; rather it is the initial public announcement of periodical financial results. Therefore it best matches an Earnings Release (ER). FY 2026
2026-05-31 English
Submission of Audited Financial Results along with Auditors Report.
Interim / Quarterly Report Classification · 90% confidence The document is a formal regulatory filing to the stock exchange under SEBI LODR Regulations, reporting the Board’s approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, accompanied by the unmodified auditor’s report and detailed financial statement tables. It contains actual financial statements and audit opinions rather than merely highlighting key figures (which would be an Earnings Release) or serving as a full annual report. Therefore, it is an Interim/Quarterly Report (IR). FY 2026
2026-05-29 English
The Board of Directors of the Company have approved the Audited Financial Results for the quarter and year ended March 31, 2026 at their meeting held on May 29, 2026.
Interim / Quarterly Report Classification · 82% confidence The document is a submission to the stock exchange under SEBI Listing Regulations reporting the Board’s approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes the full table of financial results and the Independent Auditor’s Report — it is not merely a brief earnings highlight or a notice that a report is available. This matches the definition of an Interim / Quarterly Report (IR) as it provides substantive financial statements for a period shorter than a full fiscal year (quarter plus year-to-date results) rather than a full 10-K style annual report or a simple publication announcement. FY 2026
2026-05-29 English
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Regulatory Filings Classification · 85% confidence The document is a notice under SEBI Listing Regulations to BSE about an upcoming Board of Directors meeting to approve audited financial results and related trading window closure. It is a routine regulatory announcement rather than the report itself or a management change filing. It does not present financial results, management changes, or constitute a proxy or dividend notice. Therefore, it falls under General Regulatory Filings (RNS).
2026-05-22 English
Pursuant to the Regulation 24A of SEBI (LODR) Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended March 31, 2026.
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report' for the financial year ended March 31, 2026, issued by a Practicing Company Secretary. It is addressed to the stock exchange and certifies compliance with SEBI regulations and listing obligations. The content includes compliance status, observations, and management responses related to secretarial standards and regulatory adherence. It does not contain financial statements or detailed financial performance data. The document is a compliance certification report rather than a full annual report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and compliance reports that do not contain substantive financial data.
2026-05-08 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.